Holen Sie sich die Stockscreener-App
252.38
1.16%
-2.97
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$255.35
Offen:
$254.78
24-Stunden-Volumen:
722.04K
Relative Volume:
0.71
Marktkapitalisierung:
$36.84B
Einnahmen:
$5.26B
Nettoeinkommen (Verlust:
$1.44B
KGV:
25.83
EPS:
9.7713
Netto-Cashflow:
$1.76B
1W Leistung:
-2.02%
1M Leistung:
+3.18%
6M Leistung:
-7.68%
1J Leistung:
+1.41%
1-Tages-Spanne:
$250.19
$255.62
1-Wochen-Bereich:
$250.19
$264.09
52-Wochen-Spanne:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
252.38 | 37.27B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
523.99 | 186.40B | 10.06B | 2.88B | 2.27B | 7.8807 |
|
BDX
Becton Dickinson Co
|
201.79 | 58.70B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.29 | 39.80B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
46.00 | 38.25B | 27.43B | 1.27B | 1.01B | 1.5829 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
ResMed Inc.'s (NYSE:RMD) Stock Has Fared Decently: Is the Market Following Strong Financials? - Yahoo Finance
Wealth Enhancement Advisory Services LLC Raises Stake in ResMed Inc. $RMD - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Buys 6,991 Shares of ResMed Inc. $RMD - MarketBeat
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Finviz
Vest Financial LLC Makes New Investment in ResMed Inc. $RMD - MarketBeat
ResMed (RMD) to Release Earnings on Thursday - MarketBeat
Global Sleep Apnea Devices Market is Expected to Cross the USD 15 Billion Mark by 2032 | DelveInsight - GlobeNewswire Inc.
Allstate Corp Invests $1.45 Million in ResMed Inc. $RMD - MarketBeat
ResMed Shares Garner Bullish Sentiment on Analyst Backing and Regulatory Milestone - AD HOC NEWS
ResMed officer Brett Sandercock discloses planned sale of 1,000 shares under trading plan - MSN
Vaughan David Investments LLC IL Sells 4,092 Shares of ResMed Inc. $RMD - MarketBeat
Is ResMed (NYSE:RMD) A Risky Investment? - 富途资讯
QRG Capital Management Inc. Sells 63,696 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc (NYSE:RMD) S&P 500 Chart Maps Long-Term Medical Presence - Kalkine Media
ResMed Inc. (NYSE:RMD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ResMed Inc.: How a Sleep-Tech Quiet Giant Became a Data-Driven Respiratory Powerhouse - AD HOC NEWS
Harel Insurance Investments & Financial Services Ltd. Lowers Stock Holdings in ResMed Inc. $RMD - MarketBeat
Stephens Investment Management Group LLC Has $78.02 Million Stock Position in ResMed Inc. $RMD - MarketBeat
The Truth About ResMed Inc.: Sleep Tech Stock That Quietly Went Beast Mode - AD HOC NEWS
ResMed Inc. $RMD Shares Acquired by Campbell & CO Investment Adviser LLC - MarketBeat
Should ResMed's (RMD) Earnings Beat and Margin Gains Require Action From Investors? - Yahoo Finance
ResMed Inc. (NYSE:RMD) Embodies Quality Investing Principles - Chartmill
Earnings Beat and Cash Flow Strength Could Be A Game Changer For ResMed (RMD) - Sahm
A Look At ResMed (RMD) Valuation After Earnings Beat And Strong Start To Fiscal 2026 - Yahoo Finance
Is It Time To Reassess ResMed (RMD) After Recent Sleep Care Tailwinds? - Yahoo Finance
Here's How Much a $1000 Investment in ResMed Made 10 Years Ago Would Be Worth Today - sharewise.com
Resmed promotes new chief strategy officer from within - MassDevice
Reflecting On Patient Monitoring Stocks’ Q3 Earnings: ResMed (NYSE:RMD) - Barchart.com
Shorts Report: Can ResMed Inc maintain sales growthWeekly Investment Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Nordea Investment Management AB Acquires 26,629 Shares of ResMed Inc. $RMD - MarketBeat
Sumitomo Mitsui Trust Group Inc. Buys 4,222 Shares of ResMed Inc. $RMD - MarketBeat
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term - sharewise.com
ResMed (RMD): Buy, Sell, or Hold Post Q3 Earnings? - Barchart.com
ResMed Inc. Announces Change in Board Leadership - MSN
ResMed Chairman Emeritus Peter Farrell Sells 2,000 Shares Under Trading Plan - TipRanks
ResMed CEO Michael Farrell Exercises Options and Sells Shares Under 10b5-1 Plan - TipRanks
ResMed updates CDI and share structure for December 2025 - MSN
A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD) - Yahoo Finance
Bogart Wealth LLC Boosts Position in ResMed Inc. $RMD - MarketBeat
Aug PostEarnings: What dividend growth rate does ResMed Inc offerJuly 2025 Gainers & Real-Time Buy Signal Notifications - baoquankhu1.vn
What you need to know ahead of ResMed's earnings release - MSN
Zacks Research Comments on ResMed's Q2 Earnings (NYSE:RMD) - MarketBeat
The Truth About ResMed Inc.: Is This Sleep Tech Stock Quietly Going Viral? - AD HOC NEWS
Oregon Public Employees Retirement Fund Has $4.58 Million Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. Reports Changes in Beneficial Ownership - MSN
How ResMed Inc. stock performs in easing cyclesIndex Update & Reliable Intraday Trade Alerts - ulpravda.ru
Resmed Insider Sold Shares Worth $497,660, According to a Recent SEC Filing - marketscreener.com
Insider Selling: ResMed (NYSE:RMD) Director Sells 2,000 Shares of Stock - MarketBeat
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus
Resmed director Farrell sells $497k in shares By Investing.com - Investing.com UK
Resmed director Farrell sells $497k in shares - Investing.com
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.09%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):